Bavarian To Buy Emergent BioSolutions Vaccines For $380M
Law 360 M&A
FEBRUARY 15, 2023
Danish biotechnology company Bavarian Nordic AS said Wednesday it will acquire three travel vaccines and related assets from U.S. rival Emergent BioSolutions Inc. for $380 million, in a deal guided by Cooley LLP and Barnes & Thornburg LLP.
Let's personalize your content